Literature DB >> 3240766

The effects of once-daily dosing with ranitidine and cimetidine on theophylline pharmacokinetics.

J McEwen1, M E McMurdo, T A Moreland.   

Abstract

Twelve healthy non-smokers (7M and 5F) completed a balanced three-way crossover investigation designed to characterise the influence of oral cimetidine (800 mg), ranitidine (300 mg) and placebo pretreatment for 7 days on the pharmacokinetics of a 250 mg single oral dose of theophylline. The oral clearance of theophylline after ranitidine pretreatment, 4.55 +/- 1.69 l/h (mean +/- SD) was indistinguishable from that after placebo, 4.78 +/- 1.96 l/h, but cimetidine was associated with a significant 21% reduction in theophylline clearance, 3.58 +/- 1.07 l/h (P = 0.006). There was a correspondingly significant increase in the terminal half-life of theophylline following cimetidine, 6.11 +/- 1.29 h (P = 0.017), compared with 5.05 +/- 1.43 h and 4.88 +/- 1.45 h for placebo and ranitidine, respectively. There was no change in maximum theophylline concentration or time to maximum but following cimetidine the plasma theophylline levels between 4 and 12 hours were 15-50% higher than following placebo (P less than 0.002). These data indicate a significant interaction between 800 mg cimetidine given once daily and theophylline which is likely to be the result of enzyme inhibition. Once-daily dosing with 300 mg ranitidine had no significant effect on theophylline pharmacokinetics.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3240766     DOI: 10.1007/BF03189940

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  7 in total

1.  [Drug interferences with theophylline. Absence of interaction between theophylline and ranitidine].

Authors:  F Ruff
Journal:  Nouv Presse Med       Date:  1982-11-20

2.  Further observations on relationships between antipyrine half-life, clearance and volume of distribution: an appraisal of alternative kinetic parameters used to assess the elimination of antipyrine.

Authors:  L G Sultatos; B H Dvorchik; E S Vesell; D G Shand; R A Branch
Journal:  Clin Pharmacokinet       Date:  1980 May-Jun       Impact factor: 6.447

3.  Effects of cimetidine and ranitidine on hepatic drug metabolism.

Authors:  K J Breen; R Bury; P V Desmond; M L Mashford; B Morphett; B Westwood; R G Shaw
Journal:  Clin Pharmacol Ther       Date:  1982-03       Impact factor: 6.875

4.  Inhibition of theophylline clearance by cimetidine but not ranitidine.

Authors:  J R Powell; J F Rogers; W A Wargin; R E Cross; F N Eshelman
Journal:  Arch Intern Med       Date:  1984-03

5.  Pharmacokinetics of theophylline and the H2-antagonist drugs cimetidine and ranitidine.

Authors:  R Dal Negro; C Pomari; O Zoccatelli; F Trevisan; C Carloni; P Turco
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1984-04

Review 6.  Histamine H2-antagonist drug interactions in perspective: mechanistic concepts and clinical implications.

Authors:  J R Powell; K H Donn
Journal:  Am J Med       Date:  1984-11-19       Impact factor: 4.965

7.  Ranitidine at very large doses does not inhibit theophylline elimination.

Authors:  H W Kelly; J R Powell; J F Donohue
Journal:  Clin Pharmacol Ther       Date:  1986-05       Impact factor: 6.875

  7 in total
  3 in total

Review 1.  Pharmacokinetic interactions between theophylline and other medication (Part II).

Authors:  R A Upton
Journal:  Clin Pharmacokinet       Date:  1991-02       Impact factor: 6.447

Review 2.  Selection of drugs to treat gastro-oesophageal reflux disease: the role of drug interactions.

Authors:  D A Flockhart; Z Desta; S K Mahal
Journal:  Clin Pharmacokinet       Date:  2000-10       Impact factor: 6.447

Review 3.  Rational prescription of drugs within similar therapeutic or structural class for gastrointestinal disease treatment: drug metabolism and its related interactions.

Authors:  Quan Zhou; Xiao-Feng Yan; Zhong-Miao Zhang; Wen-Sheng Pan; Su Zeng
Journal:  World J Gastroenterol       Date:  2007-11-14       Impact factor: 5.742

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.